AUTHORS’ COMMENTARY
| Issue | Title | |
| Vol 13, No 2 (2017) | Authors’ commentary on the article Clinical and economic analysis of effectiveness of Nivolumab (Opdivo®) use as second-line monotherapy in adult patients with advanced renal cell carcinoma after previous systemic therapy | Abstract PDF (Rus) |
| M. Y. Frolov | ||
| 1 - 1 of 1 Items | ||
